The India-Africa Forum Summit IV, initially set for 28–31 May in New Delhi, was delayed due to concerns over the Bundibugyo Ebola outbreaks. A report highlighted India’s crucial role as a rapid vaccine producer for Africa, emphasizing the Serum Institute of India’s swift vaccine production efforts.
The postponement of the summit shed light on India’s significant contribution to fast-tracking vaccine production through the Serum Institute of India (SII). This move positioned New Delhi as a key partner in providing urgent and efficient interventions for Africa.
The Bundibugyo Ebola outbreaks in the Democratic Republic of Congo and Uganda raised apprehensions about the safety and participation of African leaders and delegations. The Serum Institute of India, in collaboration with CEPI, Oxford, and African stakeholders, mirrored India’s proactive approach in combating Covid-19 by swiftly intervening to produce vaccines for the Global South, including African nations.
SII, utilizing ChAdOx1 technology, is working on developing a vaccine for the Bundibugyo strain, with expectations that clinical-grade doses could be available for trials within two to three months. This rapid response has positioned India as a dependable partner for Africa, focusing on ensuring affordable access for affected nations while collaborating closely with African counterparts on trial readiness and distribution planning.
The African Union, in partnership with the Africa Centres for Disease Control, has declared a Public Health Emergency and is advocating for vaccines to be available by the end of the year. While the core research and development (R&D) and manufacturing for the vaccine are sourced from other countries, India’s support extends beyond vaccines, with significant donations to countries like Burkina Faso, Malawi, and Mozambique.
Partnerships with India, CEPI, Oxford, and other entities play a crucial role in bridging gaps, but achieving true self-reliance necessitates sustained investments in local biotech, technology transfer, and unified regulatory frameworks.
